JP2004527452A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004527452A5 JP2004527452A5 JP2002504307A JP2002504307A JP2004527452A5 JP 2004527452 A5 JP2004527452 A5 JP 2004527452A5 JP 2002504307 A JP2002504307 A JP 2002504307A JP 2002504307 A JP2002504307 A JP 2002504307A JP 2004527452 A5 JP2004527452 A5 JP 2004527452A5
- Authority
- JP
- Japan
- Prior art keywords
- thrombomodulin
- analog
- modified
- native
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100026966 Thrombomodulin Human genes 0.000 description 62
- 108010079274 Thrombomodulin Proteins 0.000 description 62
- 239000008194 pharmaceutical composition Substances 0.000 description 18
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 6
- 108090000190 Thrombin Proteins 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 230000004913 activation Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 108090000201 Carboxypeptidase B2 Proteins 0.000 description 2
- 102100035023 Carboxypeptidase B2 Human genes 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 102000012545 EGF-like domains Human genes 0.000 description 2
- 108050002150 EGF-like domains Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 241001519451 Abramis brama Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 238000011905 homologation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21367800P | 2000-06-21 | 2000-06-21 | |
| US60/213,678 | 2000-06-21 | ||
| US09/880,484 | 2001-06-12 | ||
| US09/880,484 US6632791B1 (en) | 2000-06-21 | 2001-06-12 | Thrombomodulin analogs for pharmaceutical use |
| PCT/US2001/019590 WO2001098352A2 (en) | 2000-06-21 | 2001-06-20 | Thrombomodulin analogs for pharmaceutical use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004527452A JP2004527452A (ja) | 2004-09-09 |
| JP2004527452A5 true JP2004527452A5 (https=) | 2008-08-07 |
| JP4855627B2 JP4855627B2 (ja) | 2012-01-18 |
Family
ID=26908302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002504307A Expired - Fee Related JP4855627B2 (ja) | 2000-06-21 | 2001-06-20 | 医薬用途のためのトロンボモジュリン |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6632791B1 (https=) |
| EP (1) | EP1292673B1 (https=) |
| JP (1) | JP4855627B2 (https=) |
| AT (1) | ATE309339T1 (https=) |
| AU (1) | AU2001269927A1 (https=) |
| DE (1) | DE60114819T2 (https=) |
| DK (1) | DK1292673T3 (https=) |
| ES (1) | ES2256266T3 (https=) |
| NO (1) | NO20026147L (https=) |
| WO (1) | WO2001098352A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030118580A1 (en) * | 2001-11-09 | 2003-06-26 | Rasmus Rojkjaer | Pharmaceutical composition comprising factor VII polypeptides and thrombomodulin polypeptides |
| US7579000B2 (en) * | 2002-05-01 | 2009-08-25 | Bayer Schering Pharma Ag | Tissue factor targeted antibodies as anticoagulants |
| HK1080372A1 (zh) * | 2002-05-01 | 2006-04-28 | Schering Aktiengesellschaft | 作为抗凝剂的新型组织因子目标抗体 |
| US8012693B2 (en) | 2003-12-16 | 2011-09-06 | 3M Innovative Properties Company | Analysis of chemically crosslinked cellular samples |
| US7833978B2 (en) | 2004-02-20 | 2010-11-16 | Emory University | Thrombomodulin derivatives and conjugates |
| KR20080073293A (ko) | 2005-10-14 | 2008-08-08 | 메디뮨 엘엘씨 | 항체 라이브러리의 세포 디스플레이 |
| EP2120049A1 (de) | 2008-05-14 | 2009-11-18 | PAION Deutschland GmbH | Lösliches Thrombomodulin als Biomarker bei Therapien mit Gerinnungshemmern |
| WO2010006635A1 (en) * | 2008-07-16 | 2010-01-21 | Paion Deutschland Gmbh | Treatment of inflammatory bowel disease |
| EP2320936A1 (en) * | 2008-07-16 | 2011-05-18 | PAION Deutschland GmbH | Prevention and treatment of radiation injury |
| US20120165244A1 (en) * | 2008-10-30 | 2012-06-28 | Hua-Lin Wu | Methods for binding lewis y antigen |
| AU2009347614A1 (en) * | 2009-06-12 | 2012-01-19 | Paion Deutschland Gmbh | Treatment of coagulopathy with hyperfibrinolysis |
| CL2011001887A1 (es) | 2010-08-05 | 2012-02-03 | Council Scient Ind Res | Construcciones de proteinas quimericas que poseen propiedades anticoagulantes y tromboliticas; secuencia de acido nucleico que las codifica; vector; celula huesped; metodo de preparacion; formulacion farmaceutica que las comprende; y su uso para inhibir la trombina. |
| WO2014020183A1 (de) * | 2012-08-03 | 2014-02-06 | Ici Immunochemical Intelligence Gmbh | In-vitro-assay zur diagnose von störungen der hämostase |
| US9156904B2 (en) * | 2013-07-29 | 2015-10-13 | Blue Blood Biotech Corp. | Thrombomodulin variants and use thereof |
| US11085031B2 (en) * | 2016-04-28 | 2021-08-10 | Saint Louis University | Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256770A (en) | 1990-04-09 | 1993-10-26 | Schering Ag | Oxidation resistant thrombomodulin analogs |
| US5466668A (en) | 1989-04-28 | 1995-11-14 | Schering Aktiengesellschaft | Superior thrombomodulin analogs for pharmaceutical use |
| US6063763A (en) | 1989-04-28 | 2000-05-16 | Schering Aktiengesellschaft | Protease-resistant thrombomodulin analogs |
| AU4533093A (en) * | 1992-06-10 | 1994-01-04 | Michael John Morser | Mutants of the epidermal growth factor domains of human thrombomodulin |
-
2001
- 2001-06-12 US US09/880,484 patent/US6632791B1/en not_active Expired - Fee Related
- 2001-06-20 JP JP2002504307A patent/JP4855627B2/ja not_active Expired - Fee Related
- 2001-06-20 EP EP01948487A patent/EP1292673B1/en not_active Expired - Lifetime
- 2001-06-20 AU AU2001269927A patent/AU2001269927A1/en not_active Abandoned
- 2001-06-20 DK DK01948487T patent/DK1292673T3/da active
- 2001-06-20 ES ES01948487T patent/ES2256266T3/es not_active Expired - Lifetime
- 2001-06-20 AT AT01948487T patent/ATE309339T1/de active
- 2001-06-20 WO PCT/US2001/019590 patent/WO2001098352A2/en not_active Ceased
- 2001-06-20 DE DE60114819T patent/DE60114819T2/de not_active Expired - Lifetime
-
2002
- 2002-12-20 NO NO20026147A patent/NO20026147L/no not_active Application Discontinuation
-
2003
- 2003-05-14 US US10/438,648 patent/US6790828B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004527452A5 (https=) | ||
| CA2529179A1 (en) | Recombinant adeno-associated virus vector for treatment of alzheimer disease | |
| EP1197220A3 (en) | Therapeutic methods and compositions based on delta proteins and nucleic acids | |
| EP2875826A1 (en) | Composition for preventing or treating sepsis | |
| CA2165197A1 (en) | Recombinant stratum corneum chymotryptic enzyme (scce) | |
| EP1440980A3 (en) | Peptide analogs of human myelin basic protein | |
| WO2000024893A3 (en) | Methods and compositions for the prevention and treatment of anemia | |
| AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
| WO2003093299A3 (en) | Insulin-associated peptides with effects on cerebral health | |
| KR880000463A (ko) | 사슬 결합법 | |
| KR20200078413A (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물 | |
| KR101943978B1 (ko) | 신규한 펩타이드 | |
| WO2002002133A3 (en) | Peptide composition for treatment of periodontal diseases and prevention of skin aging | |
| MX9703642A (es) | Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana. | |
| WO2004009625A3 (en) | PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF α-SYNUCLEIN-RELATED DISEASES | |
| AU2025220790A1 (en) | Pharmaceutical composition for preventing or treating periodontal disease or luxated teeth | |
| JP2002522508A5 (https=) | ||
| FR2766191B1 (fr) | Peptides anti-microbiens de crustaces | |
| NZ508816A (en) | Bactericidal/permeability-increasing protein (BPI) deletion analogs | |
| JP2004538320A5 (https=) | ||
| WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
| CA2365266A1 (en) | Soybean protein nutraceuticals | |
| JP2004521076A5 (https=) | ||
| IL143956A (en) | Chimeric polypeptide having the antigenic determinants of four proteins of l. infantum, polynucleotides encoding same, methods of production and use thereof in therapeutic compositions | |
| WO2000058466A3 (en) | Protease resistant flint analogs |